Quantification of myocardial iron overload by cardiovascular magnetic resonance imaging T2* and review of the literature

Clinical Cardiology

Volumn 32, Issue 6, 2009, Pages E54-E58

  Kondur, Ashok K ^a   Li, Tao ^a   Vaitkevicius, Peter ^a   Afonso, Luis ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Cardiac magnetic resonance imaging T2*; Ferritin; Heart failure; Hemochromatosis; Myocardial iron overload; Siderosis

Indexed keywords

CONTRAST MEDIUM; DEFEROXAMINE;

ADULT; ARTICLE; BETA THALASSEMIA; CARDIOMYOPATHY; CASE REPORT; CHELATION THERAPY; CLINICAL EXAMINATION; CONGESTIVE HEART FAILURE; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; DYSPNEA; ERYTHROCYTE TRANSFUSION; FEMALE; HEART DILATATION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE PERFUSION; HUMAN; IRON CHELATION; IRON OVERLOAD; LIVER CIRRHOSIS; PAROXYSMAL DYSPNEA; PERFUSION WEIGHTED IMAGING; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 67650458635     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20310     Document Type: Article

References (19)

1. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, et al.: Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171-2179. (Pubitemid 33139463)
2. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, et al.: High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol. 1990;84:113-117. (Pubitemid 20361934)
3. Davis BA, Porter JB: Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000;95:1229-1236. (Pubitemid 30099831)
4. Nienhuis AW, Griffith P, Strawczynski H, Henry W, Borer J, et al.: Evaluation of cardiac function in patients with thalassemia major. Ann N Y Acad Sci. 1980;344:384-396. (Pubitemid 11140748)
5. Buja LM, Roberts WC: Iron in the heart. Etiology and clinical significance. Am J Med. 1971;51:209-221.
6. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, et al.: Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascularmagnetic resonance. Br J Haematol. 2004;127:348-355. (Pubitemid 39468951)
7. Westwood MA, Anderson LJ, Firmin DN, Gatehouse PD, Lorenz CH, et al.: Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia. J Magn Reson Imaging. 2003;18:616-620. (Pubitemid 37345172)
8. Ghugre NR, Enriquez CM, Coates TD, Nelson MD Jr, Wood JC: Improved R2* measurements in myocardial iron overload. J Magn Reson Imaging. 2006;23:9-16. (Pubitemid 43100712)
9. Pepe A, Positano V, Santarelli MF, Sorrentino F, Cracolici E, et al.: Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. J Magn Reson Imaging. 2006;23:662-668.
10. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD: Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103:1934-1936. (Pubitemid 38268994)
11. Mavrogeni S, Gotsis ED, Berdousi E, Ladis V, Verganelakis D, et al.: Myocardial and hepatic T2* magnetic resonance evaluation in ex-thalassemic patients after bone-marrow transplantation. Int J Cardiovasc Imaging. 2007;1569-5794. (Pubitemid 350055697)
12. Chacko J, Pennell DJ, Tanner MA, Hamblin TJ, Wonke B, et al.: Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol. 2007;138:587-593. (Pubitemid 47206717)
13. Mavrogeni SI, Markussis V, Kaklamanis L, Tsiapras D, Paraskevaidis I, et al.: A comparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with beta-thalassemia major. Eur J Haematol. 2005;75:241-247. (Pubitemid 41153105)
14. Konen E, Ghoti H, Goitein O, Winder A, Kushnir T, et al.: No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2* technique. Am J Hematol. 2007;82:1013-1016. (Pubitemid 350004394)
15. Westwood MA, Sheppard MN, Awogbade M, Ellis G, Stephens AD. et al.:Myocardial biopsy and T2* magnetic resonance in heart failure due to thalassaemia. Br J Haematol. 2005;128:2.
16. Cheong B, Huber S, Muthupillai R, Flamm SD: Evaluation of myocardial iron overload by T2* cardiovascular magnetic resonance imaging. Tex Heart Inst J. 2005;32:448-449. (Pubitemid 41306819)
17. Ghugre NR, Enriquez CM, Gonzalez I, Nelson MD Jr, Coates TD, et al.: MRI detects myocardial iron in the human heart. Magn Reson Med. 2006;56:681-686. (Pubitemid 44338890)
18. Wood JC, Otto-Duessel M, Aguilar M, Nick H, Nelson MD, et al.: Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation. 2005;112: 535-543. (Pubitemid 41060794)
19. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, et al.: A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876-1884. (Pubitemid 46598901)